Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04620798 · ClinicalTrials.gov registry record · NA

Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students

A NA study, sponsored by Indiana University.

Completed
Registry status
NA
Development phase
1,076
Enrollment target

NCT04620798: Completed NA study, sponsored by Indiana University.

NCT04620798 is a NA study that has completed, run by Indiana University. The registered enrollment target is 1,076 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04620798, a NA study, has completed, sponsored by Indiana University.

COMPLETED
Registry status
NA
Development phase
1,076 participants
Enrollment target

Study Summary

The primary goal for this study is to assess whether receiving the results of an antibody test changes protective behavior to avoid SARS-CoV-2 infections (i.e., mask-wearing, physical distancing, limiting close contacts/avoiding crowds, hand-washing, avoiding contact with high-risk individuals). While studies have been published on the cross-sectional relationship between risk perception and other demographic characteristics and health behaviors that are protective for SARS-CoV-2 infection (see citations), there have been no studies showing the effect of receiving information about antibody positivity on protective behavior. Not only can results from this study be used to better model transmission, a better understanding of college student's risk perception around SARS-CoV-2 infections has implications for future vaccination strategies as well. There are concerns that a desire to return to "normal" life in combination with reduced perception of risk could have negative consequences for uptake of vaccination (Johns Hopkins Center for Health Security 2020 report, The Public's Role in COVID-19 Vaccination: Planning Recommendations Informed by Design Thinking and the Social, Behavioral, and Communication Sciences). The antibody test used in this study is named 'SARS-CoV-2 IgM/IgG rapid assay kit (Colloidal Gold)'. It provides a fast, on-site, and accurate detection of IgM/IgG antibodies against SARS-CoV-2, with positive results of IgM antibodies indicating a recent infection, while positive results of IgG antibodies signaling a longer or previous infection. It can detect IgM and IgG antibodies against SARS-CoV-2 in human specimens of serum, plasma, or venous whole blood.

Primary Outcome

This outcome was dichotomized into Always and Very Often versus Sometimes, Rarely, and Never. It will be self-reported in a web-based follow-up survey administered at 2 weeks after the baseline antibody test, with an item adapted from the WHO 2020 "Monitoring knowledge, risk perceptions, preventive behaviours and trust to inform pandemic outbreak response": "During the last 7 days, which of the following measures have you taken to prevent infection from COVID-19?" -Frequently washed my hands w

Interventions

  • BEHAVIORAL Immediate vs. delayed provision of antibody test results

Trial Details

FieldValue
Enrollment Target 1,076 participants
Start Date 2020-09-14
Est. Completion 2020-11-11
Phase NA
Indiana University

890 total trials

What the finished NCT04620798 record still lists

NCT04620798 is an interventional study that assigns participants to a tested intervention. Its 1,076 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (23% lower).

The record links to 0 conditions, and to 1 intervention - of which Immediate vs. delayed provision of antibody test results is the first listed.

NCT04620798 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04620798 about?

NCT04620798 is a clinical study titled "Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students". The primary goal for this study is to assess whether receiving the results of an antibody test changes protective behavior to avoid SARS-CoV-2 infections (i.e., mask-wearing, physical distancing, limiting close contacts/avoiding crowds, hand-washing, avoiding contact with high-risk individuals). Whi...

What is the current status of trial NCT04620798?

This trial is currently completed. It is a NA study. The enrollment target is 1,076 participants. The study started on 2020-09-14. Estimated completion is 2020-11-11.

What interventions are being tested in trial NCT04620798?

The interventions under investigation include: Immediate vs. delayed provision of antibody test results (BEHAVIORAL).

Who is sponsoring clinical trial NCT04620798?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04620798's enrollment target sits among peer trials

1,076 95th of 2000 higher than 1,906 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07084883 · 1,076 participants

    Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration

  • NCT06658808 · 1,075 participants · NA

    Efficacy-Implementation Study for PC CARES in Rural Alaska

  • NCT06159673 · 1,074 participants · Phase 2

    ACP-204 in Adults With Alzheimer's Disease Psychosis

  • NCT06074068 · 1,080 participants · NA

    Father-Focused Intervention for Reducing Family Violence and Symptoms in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04620798, the US trial registry maintained by the National Library of Medicine. NCT04620798 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.